Navigation Links
Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma

cular ejection fraction has been reported, including reports in patients with few or no risk factors for decreased left ventricular ejection fraction. There have been rare reports of acute diffuse infiltrative pulmonary disease of unknown etiology such as pneumonitis, interstitial pneumonia, lung infiltration and Acute Respiratory Distress Syndrome in patients receiving VELCADE. Some of these events have been fatal. A higher proportion of these events have been reported in Japan. There have been rare reports of RPLS in patients receiving VELCADE. RPLS is a rare, reversible, neurological disorder which can present with seizure, hypertension, headache, lethargy, confusion, blindness, and other visual and neurological disturbances. VELCADE is associated with thrombocytopenia and neutropenia. There have been reports of gastrointestinal and intracerebral hemorrhage in association with VELCADE. Transfusions may be considered. Complete blood counts (CBC) should be frequently monitored during treatment with VELCADE. Rare cases of acute liver failure have been reported in patients receiving multiple concomitant medications and with serious underlying medical conditions.

Safety Data: In 1163 patients in multiple myeloma and mantle cell lymphoma studies, the most commonly reported adverse events were asthenic conditions (64%), nausea (55%) in single-agent VELCADE, diarrhea (52%), constipation (41%), peripheral neuropathy (39%), thrombocytopenia (36%), appetite decrease, including reports of anorexia (36%), pyrexia (34%), vomiting (33%) and anemia (29%). Twenty percent of patients reported at least one episode of grade 4 toxicity; the most common grade 4 toxicities were thrombocytopenia (5%) and neutropenia (3%). Fifty percent of patients reported serious adverse events. The most commonly reported serious adverse events were pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, dyspnea and thrombocytopenia (each 3%).

For more informa
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
2. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
3. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
4. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
5. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
6. Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection
7. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
10. Aquavan (Fospropofol Disodium) Injection Data Presented at Digestive Disease Week 2007
11. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
Post Your Comments:
(Date:7/1/2015)... -- According to a new market research ... (Calcium Phosphate, Lipofection, Dendrimers), Physical (Electroporation, Nucleofection), Viral), by ... to 2020", published by MarketsandMarkets, the Transfection Reagents and ... by 2020 with a CAGR of 7.2% from 2014 ... ables and 33 F igures ...
(Date:7/1/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/nk3569/future_horizons ... "Future Horizons and Growth Strategies in the European ... Forecasts" report to their offering. ... Blood Banking Market 2015 is a new five-countrystrategic ... and potential market entrants identify and evaluate emerging ...
(Date:7/1/2015)... MARLBOROUGH, Mass. , July 1, 2015 Boston ... call discussing financial results and business highlights for the second ... at 8 a.m. ET. The call will be ... officer, and Dan Brennan , executive vice president and ... conference call will be available via the Boston Scientific website. ...
Breaking Medicine Technology:Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 2Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 3Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 4European Blood Banking 2015: Future Horizons and Growth Strategies - Supplier Shares and Country Forecasts 2European Blood Banking 2015: Future Horizons and Growth Strategies - Supplier Shares and Country Forecasts 3Boston Scientific To Webcast Second Quarter 2015 Earnings Call On July 23 2
... TechniScan (OTC Bulletin Board: TSNI ), a ... an automated 3D breast ultrasound imaging system, announced today that ... with Austin, Texas-based Womens3D. These agreements follow ... January 2011 in which they agreed to jointly develop a ...
... PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ... company,s president and chief executive officer, is scheduled ... Markets Healthcare ConferenceWednesday, March 2, 20119:00 a.m. Eastern ... Health Care Conference Tuesday, March 8, 201111:00 a.m. ...
Cached Medicine Technology:Breast Imaging Company, TechniScan, Signs Manufacturing Agreement With Texas Company 2
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... exclusively to healthcare providers, has been retained to lead a national chief ... the top executive search firms in the healthcare industry, B. E. Smith has ...
(Date:7/1/2015)... , ... July 01, 2015 , ... Incentivizing the use ... under control, with discounts as much as 80% or 90% off the prices for ... insurers need to act to mitigate the financial impact of these high-cost generic drugs. ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... the global distribution and marketing of a number of nutritional and beauty products, ... attended the 2015 ECRM Diet, Vitamin & Sports Nutrition conference in Tampa, Florida. ...
(Date:7/1/2015)... , ... July 01, 2015 , ... ... platforms and devices, today announced the opening of a new operational office in ... support that enables collaboration across all lines of business for organizations throughout the ...
(Date:7/1/2015)... ... July 01, 2015 , ... First Harvest Financial ... web-based resource where legal cannabis startups can interact with corporate executives, ... medical marijuana advocates looking to strategically enter and capitalize on growing and creating ...
Breaking Medicine News(10 mins):Health News:Citizens Medical Center Retains B. E. Smith to Recruit New CEO 2Health News:Citizens Medical Center Retains B. E. Smith to Recruit New CEO 3Health News:Blues Execs Share Strategies for Managing Generic Drug Inflation in AIS Newsletter 2Health News:Blues Execs Share Strategies for Managing Generic Drug Inflation in AIS Newsletter 3Health News:NPI Executives Report Great Success at ECRM Conference 2Health News:AvePoint Opens Office in Zurich to Meet Increasing Market Demand for Enterprise Collaboration Solutions in Switzerland 2Health News:AvePoint Opens Office in Zurich to Meet Increasing Market Demand for Enterprise Collaboration Solutions in Switzerland 3Health News:First Harvest Financial Partners in Launch of Legal Medical Cannabis Documentary Initiative 2Health News:First Harvest Financial Partners in Launch of Legal Medical Cannabis Documentary Initiative 3
... Julia VanTine HealthDay Reporter , WEDNESDAY, Oct. 27 ... than commonly thought, say researchers who found a lag time ... mutations and the formation of the first cancer cells. ... this often-fatal disease in its early stages, scientists say. ...
... WEDNESDAY, Oct. 27 (HealthDay News) -- Although many Americans are ... many are controlling the condition, the prevalence of high blood ... health officials report. According to a new ... 30 percent of American adults suffer from hypertension. "Overall, ...
... immune system may play a critical role in ensuring the ... new study by researchers at the Stanford University School of ... oncogenes are much more successful in eradicating tumors in the ... cell called a T helper cell. The finding is ...
... Hatfield Professor of Urology in the Department of Urology at ... honored as the 2010 recipient of the Karl Storz Lifetime ... He is also a full Professor of Radiology. ... the Karl Storz lifetime achievement award; having such a distinguished ...
... , WEDNESDAY, Oct. 27 (HealthDay News) -- With ... expert offers breast cancer survivors some guidance on what ... Karen Syrjala, director of biobehavioral sciences and co-director ... Research Center in Seattle, touches upon both the lingering ...
... A team investigating how genes respond to hormonal changes ... of 1.24 million for a five-year study. The ... Manchester Biomedical Research Centre (BRC) is led by Professor ... and leader of The University of Manchester,s Developmental Biomedicine ...
Cached Medicine News:Health News:Pancreatic Cancer Surprisingly Slow to Arise: Study 2Health News:Pancreatic Cancer Surprisingly Slow to Arise: Study 3Health News:Percentage of U.S. Adults With Hypertension Holds Steady at 30% 2Health News:Certain cancer therapies' success depends on presence of immune cell, Stanford study shows in mice 2Health News:Certain cancer therapies' success depends on presence of immune cell, Stanford study shows in mice 3Health News:Certain cancer therapies' success depends on presence of immune cell, Stanford study shows in mice 4Health News:Jefferson urologist awarded Lifetime Achievement Award from Endourological Society 2Health News:Women Urged to Reclaim Their Life After Breast Cancer 2Health News:Manchester team wins $1.9 million grant for 'cell control' study 2
For the qualitative detection of IgG/IgM antibodies to B. burgdorferi...
... surgical-quality loupes available at manufacturer-direct ... innovative optical design, combining superior quality ... with maximum comfort, SheerVision loupes are ... worldwide. Make both a professional and ...
... surgical-quality loupes available at manufacturer-direct ... innovative optical design, combining superior quality ... with maximum comfort, SheerVision loupes are ... worldwide. Make both a professional and ...
... the first manufacturer to offer through-the-lens ... wearer. These next generation loupes feature ... ultra-lightweight design, and are multi-coated lens ... With SheerVision's proprietary SureFit system - ...
Medicine Products: